Methods of treatment
This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.
1. A compound selected from:
or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
2. A pharmaceutical composition comprising a compound of claim 1 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
3. The compound of claim 1 , which is
or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
4. The compound of claim 1 , which is
or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
5. The compound of claim 1 , which is
or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
6. A pharmaceutical composition comprising the compound of claim 3 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
7. A pharmaceutical composition comprising the compound of claim 4 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
8. A pharmaceutical composition comprising the compound of claim 5 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
9. A method for increasing hemoglobin oxygen affinity in a human in need thereof comprising administering to the human a compound of claim 1 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
10. The method of claim 9 , wherein the hemoglobin is hemoglobin S.
11. A method for increasing hemoglobin oxygen affinity in a human in need thereof comprising administering to the human the compound of claim 3 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
12. A method for increasing hemoglobin oxygen affinity in a human in need thereof comprising administering to the human the compound of claim 4 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
13. A method for increasing hemoglobin oxygen affinity in a human in need thereof comprising administering to the human the compound of claim 5 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
14. A method for treating sickle cell disease in a human in need thereof comprising administering to the human a compound of claim 1 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
15. A method for treating sickle cell disease in a human in need thereof comprising administering to the human the compound of claim 3 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
16. A method for treating sickle cell disease in a human in need thereof comprising administering to the human the compound of claim 4 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.
17. A method for treating sickle cell disease in a human in need thereof comprising administering to the human the compound of claim 5 , or a stereoisomer thereof, or a pharmaceutically acceptable salt of each thereof.